What should you know about neuroblastoma cells in bone marrow?

Bone marrow is the soft tissue inside many bones where blood cells are made. Neuroblastoma cells can travel there from a tumour elsewhere in the body. A marrow result is interpreted alongside scans, urine or blood tests, the primary tumour’s features and the child’s age. It can influence risk grouping and the intensity or sequence of treatment; it is not interpreted in isolation.

Bone marrow involvement may reduce healthy blood-cell production or may not cause noticeable symptoms. Low red cells can contribute to tiredness, low platelets can make bruising or bleeding easier, and low infection-fighting cells can increase infection risk. The oncology team monitors blood counts during assessment and treatment.

Ask the team to explain the marrow report in plain language, including whether cells were found in one or more samples and how the result changes the plan. Keep a record of temperatures, medicines and symptoms. Treatment may include systemic medicines, surgery for the primary tumour, or selected radiation-based treatment. These options are discussed in [Chemotherapy](/treatments/systemic-therapy/chemotherapy/), [Tumour Removal Surgery](/treatments/surgical-oncology/tumour-removal-surgery/) and [Targeted Radioisotope Therapy](/treatments/radiation-oncology/targeted-radioisotope-therapy/).

Contact the oncology team urgently for fever, chills, breathing difficulty, unusual bleeding, black stools, severe weakness or a child who is difficult to wake. Do not wait for a routine appointment if infection or significant bleeding is possible during treatment.

Ask what the marrow sample showed, how certain the result is, whether more sampling is needed, and how it affects risk grouping. Discuss expected blood-count changes, infection precautions, transfusion support if needed, treatment goals and how response will be checked.